Zacks Report Highlights Flora Growth Corp. (NASDAQ: FLGC) Aspiring to Benefit from First Mover Advantage in Multiple Cannabis Market Categories
- Flora’s 2021 acquisitions allowed it to expand its operations beyond North America and into Europe
- Acquisitions have also contributed to 450% YOY revenue growth for Q1 2022
- Its management is confident that the foundation laid down so far will yield growth for 2022 and subsequent financial years
- Flora has also reiterated 2022 revenue guidance of $35 million to $45 million
2021 was an excellent year for Flora Growth (NASDAQ: FLGC). According to a recent research report from Zacks (https://nnw.fm/gIo9F ), the company possesses a number of important qualities pointing to continued significant growth following a strong 2021. Flora Growth management even regarded the past year as “transformational,” particularly following the closing of supplier, vendor, and distribution agreements that would see the company expand its operations, market reach, and product line.
With the progress made by the company so far, it is looking to benefit from a first-mover advantage in multiple market categories in terms of increased value for its shareholders, a higher market share, and increased revenue going forward.
The report went on to talk about 2021’s acquisition of Vessel Brand, Inc., a move that allowed the company to establish a foothold in the United States cannabis accessories business while improving its e-commerce capabilities. The year would also see the construction of an all-outdoor cultivation and on-site extraction facility in Colombia, one of the largest traditional flower exporters in the world and now able to export cannabis flowers.
Such moves position Flora to take advantage of the potential of the marijuana industry, particularly the medical marijuana sector. According to a report from Grand View Research, the global medical marijuana market size was valued at USD 11.0 billion in 2021 and is projected to expand at a compound annual growth rate (“CAGR”) of 21.6% from 2022 to 2030 (https://nnw.fm/VqL0C ).
Through its acquisitions, Flora has expanded its operations beyond North America and into Europe. The company’s investment in Hoshi International, for instance, opened it to the European Union (“EU”), allowing it to expand its global footprint that would further spread to Hong Kong, Latin America, and Israel.
The report also pointed out Flora’s Life Sciences pillar, one of its three key pillars of growth, focused on providing scientific-based research associated with cannabis. The other two pillars include Commercial and Wholesale and House of Brands. The company believes that, while offering the products in its portfolio is critical, educating consumers and potential customers is of the essence if the conversation around cannabis is to be advanced. Therefore, Flora remains committed to creating educational platforms and conducting research studies and clinical trials to develop plant-based, medical-grade pharmaceuticals, phytotherapeutics, and dietary supplements.
Through its acquisitions and growing distribution network, Flora was able to post a 450% year-over-year revenue growth for the first quarter of the 2022 financial year. As a result, its management is confident that, for the entire fiscal year, the company will post between $35 million and $45 million in revenue.
This will be significantly influenced by the JustCBD acquisition, the awarding of an export quota for 43.6 tons of high-THC cannabis in Colombia, and the successful completion of the requisite steps to allow for the commercial planting and export of psychoactive cannabis.
Flora looks to reach cash flow breakeven as revenue continues to ramp, having closed the 2021 fiscal year with about $37.6 million in cash and a $21.4 million loss. 2021 was its first full year of revenue. Still, the company anticipates accelerating revenue growth in 2022 as it activates its Wholesale and Life Sciences growth units while simultaneously fueling expansion in the global House of Brands.
Flora is aggressively pushing its brand and advancing the conversation around cannabis. In addition, with its able management, Flora is recognizing and capitalizing on opportunities that others are yet to identify, placing it in a unique position that not only gives it a first-mover advantage, but also presents a unique opportunity for growth.
The full Zacks Small-Cap Research Report is available at https://nnw.fm/gIo9F.
For more information, visit the company’s website at www.FloraGrowth.com.
NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://nnw.fm/FLGC
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Flora’s 2021 acquisitions allowed it to expand its operations beyond North America and into Europe
- Acquisitions have also contributed to 450% YOY revenue growth for Q1 2022
- Its management is confident that the foundation laid down so far will yield growth for 2022 and subsequent financial years
- Flora has also reiterated 2022 revenue guidance of $35 million to $45 million
2021 was an excellent year for Flora Growth (NASDAQ: FLGC). According to a recent research report from Zacks (https://nnw.fm/gIo9F ), the company possesses a number of important qualities pointing to continued significant growth following a strong 2021. Flora Growth management even regarded the past year as “transformational,” particularly following the closing of supplier, vendor, and distribution agreements that would see the company expand its operations, market reach, and product line.
With the progress made by the company so far, it is looking to benefit from a first-mover advantage in multiple market categories in terms of increased value for its shareholders, a higher market share, and increased revenue going forward.
The report went on to talk about 2021’s acquisition of Vessel Brand, Inc., a move that allowed the company to establish a foothold in the United States cannabis accessories business while improving its e-commerce capabilities. The year would also see the construction of an all-outdoor cultivation and on-site extraction facility in Colombia, one of the largest traditional flower exporters in the world and now able to export cannabis flowers.
Such moves position Flora to take advantage of the potential of the marijuana industry, particularly the medical marijuana sector. According to a report from Grand View Research, the global medical marijuana market size was valued at USD 11.0 billion in 2021 and is projected to expand at a compound annual growth rate (“CAGR”) of 21.6% from 2022 to 2030 (https://nnw.fm/VqL0C ).
Through its acquisitions, Flora has expanded its operations beyond North America and into Europe. The company’s investment in Hoshi International, for instance, opened it to the European Union (“EU”), allowing it to expand its global footprint that would further spread to Hong Kong, Latin America, and Israel.
The report also pointed out Flora’s Life Sciences pillar, one of its three key pillars of growth, focused on providing scientific-based research associated with cannabis. The other two pillars include Commercial and Wholesale and House of Brands. The company believes that, while offering the products in its portfolio is critical, educating consumers and potential customers is of the essence if the conversation around cannabis is to be advanced. Therefore, Flora remains committed to creating educational platforms and conducting research studies and clinical trials to develop plant-based, medical-grade pharmaceuticals, phytotherapeutics, and dietary supplements.
Through its acquisitions and growing distribution network, Flora was able to post a 450% year-over-year revenue growth for the first quarter of the 2022 financial year. As a result, its management is confident that, for the entire fiscal year, the company will post between $35 million and $45 million in revenue.
This will be significantly influenced by the JustCBD acquisition, the awarding of an export quota for 43.6 tons of high-THC cannabis in Colombia, and the successful completion of the requisite steps to allow for the commercial planting and export of psychoactive cannabis.
Flora looks to reach cash flow breakeven as revenue continues to ramp, having closed the 2021 fiscal year with about $37.6 million in cash and a $21.4 million loss. 2021 was its first full year of revenue. Still, the company anticipates accelerating revenue growth in 2022 as it activates its Wholesale and Life Sciences growth units while simultaneously fueling expansion in the global House of Brands.
Flora is aggressively pushing its brand and advancing the conversation around cannabis. In addition, with its able management, Flora is recognizing and capitalizing on opportunities that others are yet to identify, placing it in a unique position that not only gives it a first-mover advantage, but also presents a unique opportunity for growth.
The full Zacks Small-Cap Research Report is available at https://nnw.fm/gIo9F.
For more information, visit the company’s website at www.FloraGrowth.com.
NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://nnw.fm/FLGC
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
